| 3.6571 0.087 (2.44%) | 06-10 12:20 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.01 | 1-year : | 5.85 |
| Resists | First : | 4.28 | Second : | 5.01 |
| Pivot price | 3.48 |
|||
| Supports | First : | 3.44 |
Second : | 2.93 |
| MAs | MA(5) : | 3.5 |
MA(20) : | 3.38 |
| MA(100) : | 3.64  |
MA(250) : | 4.4 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 59.9 |
D(3) : | 53.9 |
| RSI | RSI(14): 61.4 |
|||
| 52-week | High : | 6.51 | Low : | 2.23 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MNKD ] has closed below upper band by 17.7%. Bollinger Bands are 55.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.61 - 3.63 | 3.63 - 3.64 |
| Low: | 3.36 - 3.38 | 3.38 - 3.41 |
| Close: | 3.53 - 3.57 | 3.57 - 3.61 |
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Mon, 08 Jun 2026
Jim Cramer Says He Blessed MannKind as a Speculation Only - Yahoo Finance
Mon, 08 Jun 2026
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
Fri, 05 Jun 2026
Inhaled insulin data explore options for kids, pregnancy and pump users - Stock Titan
Fri, 05 Jun 2026
MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy - Yahoo Finance
Fri, 05 Jun 2026
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
Wed, 03 Jun 2026
MannKind tests inhaled IPF drug in global trial, first data Q3 2026 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 309 (M) |
| Shares Float | 303 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 59.2 (%) |
| Shares Short | 29,390 (K) |
| Shares Short P.Month | 29,580 (K) |
| EPS | -0.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.19 |
| Profit Margin | -6.7 % |
| Operating Margin | -3.4 % |
| Return on Assets (ttm) | 2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 15.1 % |
| Gross Profit (p.s.) | 0.88 |
| Sales Per Share | 1.16 |
| EBITDA (p.s.) | 0.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 19 (M) |
| Levered Free Cash Flow | 47 (M) |
| PE Ratio | -52.36 |
| PEG Ratio | 4.3 |
| Price to Book value | -19.29 |
| Price to Sales | 3.13 |
| Price to Cash Flow | 58.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|